MONDAY, May 12, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in

2025年5月12日，星期一——根据最近发表在《研究通讯》上的一封信，胰高血糖素样肽-1受体激动剂（GLP-1 RAs）与减少酒精摄入有关。

Diabetes, Obesity and Metabolism

糖尿病、肥胖与代谢

and presented at the annual meeting of the European Congress on Obesity, hosted by the European Association for the Study of Obesity from May 11 to 14 in Malaga, Spain.

并在于5月11日至14日在西班牙马拉加举办的欧洲肥胖症研究协会年度会议——欧洲肥胖大会——上发表。

Maurice O'Farrell, M.B.B.S., from the Medication Weight Loss Clinic in Dublin, and colleagues examined changes in alcohol use when patients were treated for obesity with GLP-1 RAs in a real-world setting. Data were included for 262 adults with a body mass index ≥27 kg/m

毛里斯·奥法雷尔（M.B.B.S.），来自都柏林的药物体重管理诊所，与同事在真实世界环境中研究了使用GLP-1受体激动剂治疗肥胖患者时饮酒行为的变化。研究包括262名身体质量指数≥27 kg/m²的成人数据。

2

2

who were initiated on liraglutide or semaglutide; participants were categorized into nondrinkers, rare drinkers, and regular drinkers (11.8, 19.8, and 68.3 percent, respectively).

开始使用利拉鲁肽或司美格鲁肽的患者；参与者被分为不饮酒者、偶尔饮酒者和经常饮酒者（分别占11.8%、19.8%和68.3%）。

The researchers found that none of the patients reported an increase in alcohol intake. There was a reduction in alcohol intake observed, from a preintervention mean of 11.8 ± 1.0 units/week to a postintervention mean of 4.3 ± 0.5 units/week. Reductions were confirmed in Mann-Whitney

研究人员发现，没有患者报告酒精摄入量增加。观察到酒精摄入量减少，干预前平均每周11.8 ± 1.0单位降至干预后平均每周4.3 ± 0.5单位。Mann-Whitney检验确认了这一减少。

U

你

tests in both high and low consumers, which also confirmed no significant difference in percentage reduction between men and women. After approximately four months, mean weight loss was 7.7 ± 0.3 kg, with no significant difference seen in the percentage reduction between men and women. There was a weak positive correlation noted between alcohol reduction and weight loss (r = 0.24)..

高消费者和低消费者中的测试也证实，男女之间在减少的百分比上没有显著差异。大约四个月后，平均体重减轻了7.7 ± 0.3公斤，男女之间在减少的百分比上没有看到显著差异。酒精减少和体重减轻之间存在弱正相关关系（r = 0.24）。

'The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control,' coauthor Carel Le Roux, M.D., from the Diabetes Complications Research Centre at University College Dublin, said in a statement..

“GLP-1类似物减少酒精摄入的确切机制仍在研究中，但据信它涉及抑制由大脑皮层下区域产生的非意识控制的酒精渴望，”都柏林大学学院糖尿病并发症研究中心的合著者凯瑞尔·勒鲁教授在一份声明中表示。

Abstract/Full Text

摘要/全文

More Information

更多信息

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最新资讯到您的邮箱。